


RealRate

PHARMACEUTICAL 2017




IntelGenx Technologies Corp. Rank 70 of 313





PHARMACEUTICAL 2017





The relative strengths and weaknesses of IntelGenx Technologies Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IntelGenx Technologies Corp. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 234% points. The greatest weakness of IntelGenx Technologies Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.52%, being 417% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	6,352
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,235
Liabilities, Non-Current	0
Other Assets	708
Other Compr. Net Income	-293
Other Expenses	830
Other Liabilities	2,610
Other Net Income	-199
Property and Equipment	5,730
Research and Development	1,766
Revenues	5,220
Selling, General and Administrative Expense	3,605

Output Variable	Value in 1000 USD
Assets	12,790
Liabilities	7,845
Expenses	6,201
Stockholders Equity	4,945
Net Income	-1,180
Comprehensive Net Income	-1,326
Economic Capital Ratio	0.52%

